Canadian Foundation for AIDS Research (CANFAR)   Report issue

Foundation Phase 2
Founded: Toronto Canada (1987)

Organization Overview

First Clinical Trial
2002
NCT00152893
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Alternative names

Canadian Foundation for AIDS Research (CANFAR)

Active Ingredients

Drugs in Phase 2 Trials (3)

icosapent ethyl (vascepa) (1 trial)

niacin (1 trial)

valproic acid (depakene) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

HIV Infections (Phase 2)

Hypertriglyceridemia (Phase 2)

Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3